Citadel Advisors
GRNA

Citadel Advisors’s GreenLight Biosciences Holdings, PBC Common Stock GRNA Stock Holding History

Citadel Advisors’s Portfolio GRNA Stock Details GRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-62,690
Closed -$604K – 14569
2022
Q1 		$604K Buy
+62,690
New +$562K ﹤0.01% 8941
2021
Q4 		– Sell
-287,500
Closed -$2.84M – 15140
2021
Q3 		$2.84M Buy
+287,500
New +$2.82M ﹤0.01% 5495

Other funds holding GRNA

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
VS
VK Services Menlo Park, California $543K AUM 174.84% 1-Year Est. Return
CGC
Continental Grain Company New York $366M AUM 0.18% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
TCM
Tao Capital Management San Francisco, California $119M AUM 87.46% 1-Year Est. Return
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University Redwood City, California $849M AUM 55.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors's GRNA Position: Q2 2022 in Review

Citadel Advisors sold out of GreenLight Biosciences Holdings, PBC Common Stock (GRNA) in Q2 2022, closing a stake of 62,690 shares — an estimated $604K sold.

Citadel Advisors first reported a position in GRNA in Q3 2021 and held it in 2 quarters. The position peaked at $2.84M in Q3 2021. 50 funds tracked by Wall St. Rank hold GRNA as of Q2 2022.

  • Citadel Advisors reported no remaining GreenLight Biosciences Holdings, PBC Common Stock position as of Q2 2022 after selling out during the quarter.
  • Citadel Advisors sold 62,690 GreenLight Biosciences Holdings, PBC Common Stock shares in Q2 2022, an estimated $604K.
  • Citadel Advisors first reported a position in GreenLight Biosciences Holdings, PBC Common Stock in Q3 2021 and held it in 2 quarters.
  • Citadel Advisors's GreenLight Biosciences Holdings, PBC Common Stock position peaked at $2.84M in Q3 2021.
  • 50 funds tracked by Wall St. Rank held GreenLight Biosciences Holdings, PBC Common Stock as of Q2 2022.

Based on Citadel Advisors's 13F filing for Q2 2022, filed 15 Aug 2022.